Loading clinical trials...
Loading clinical trials...
A Phase II Preventative Trial of DFMO (Eflornithine HCl) as a Single Agent in Patients With High Risk Neuroblastoma in Remission
Conditions
Interventions
DFMO
Locations
22
United States
Phoenix Children's Hospital
Phoenix, Arizona, United States
Arkansas Children's Hospital
Little Rock, Arkansas, United States
Rady Children's Hospital
San Diego, California, United States
Connecticut Children's Hospital
Hartford, Connecticut, United States
Arnold Palmer Hospital for Children
Orlando, Florida, United States
All Children's Hospital Johns Hopkins Medicine
St. Petersburg, Florida, United States
Start Date
March 5, 2015
Primary Completion Date
March 27, 2018
Completion Date
August 24, 2023
Last Updated
August 6, 2024
NCT03050268
NCT04308330
NCT06721689
NCT06395103
NCT06541262
NCT06057948
Lead Sponsor
Giselle Sholler
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions